Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: Bob Swift who wrote (3617)	8/20/1999 7:57:00 AM
From: BMcV	Read Replies (1) \| Respond to of 10280

new GERD treatment, any ideas on the chemistry--related to cisipride?: biz.yahoo.com Friday August 20, 2:00 am Eastern Time Company Press Release SOURCE: Eisai Inc. and Janssen Pharmaceutica FDA Approves New Treatment for Reflux Disease and Duodenal Ulcers Eisai and Janssen to Co-Market Aciphex(TM) (rabeprazole sodium), A New Proton Pump Inhibitor NEW YORK, Aug. 20 /PRNewswire/ -- Eisai Inc. of Teaneck, N.J. and Janssen Pharmaceutica of Titusville, N.J., today announced that Eisai Inc. has received marketing clearance from the U.S. Food and Drug Administration for Aciphex(TM) (rabeprazole sodium), a new proton pump inhibitor (PPI). Aciphex will be marketed in the United States by Eisai Inc., an affiliate of Eisai Co., Ltd. of Tokyo, Japan, and Janssen Pharmaceutica, a subsidiary of Johnson & Johnson. The FDA approved Aciphex for healing of erosive gastroesophageal reflux disease (GERD), maintenance of healed erosive GERD and healing of duodenal ulcers. Aciphex also has been approved for the treatment of pathological hypersecretory conditions, including Zollinger-Ellison syndrome. ''Our research shows that Aciphex demonstrates features, such as consistent acid control from the first dose, that should prove attractive to physicians who treat GI disorders,'' said Malcolm Robinson, MD, clinical professor of medicine at the University of Oklahoma College of Medicine, and the founder and medical director of the Oklahoma Foundation for Digestive Research. ''This new product will offer patients a highly effective treatment choice.'' More than 60 million Americans suffer from GERD and heartburn, a common GERD symptom, at least once a month, and 25 million sufferers report symptoms on a daily basis.(1) Many of these patients have severe symptoms and are often diagnosed with erosions in the lining of the esophagus, a condition called erosive GERD. Aciphex will be available in 20 mg, enteric-coated tablets to be prescribed once daily. In clinical trials, Aciphex demonstrated a favorable side-effect profile. Headache was the most common side effect assessed as possibly related to Aciphex (2.4% vs. 1.6% for placebo). Aciphex is contraindicated in patients with known sensitivity to rabeprazole, substituted benzimidazoles or any component of the formulation. As is the case for other proton pump inhibitors, symptomatic response to therapy with Aciphex does not preclude the presence of gastric malignancy. Proton pump inhibitors, however, are an established class of drugs that has been shown to be safe and well tolerated. In April 1997, Eisai Co., Ltd. and Janssen Pharmaceutica of Beerse, Belgium, formed a strategic alliance to bring the drug to market. ''Today's clearance is an important milestone for Eisai,'' said Soichi Matsuno, president of Eisai Inc. ''We believe that Aciphex represents another victory in our efforts to bring to market innovative compounds. Aciphex is a very important product for Eisai's development in the U.S., and we are delighted to receive the approval.'' In announcing the approval, David Norton, president of Janssen U.S., said, ''Aciphex represents the newest advance in PPI therapies and is an important product for Janssen. It complements our GI franchise and will be another building block for the growth of this company.'' The Japanese Ministry of Health and Welfare cleared rabeprazole sodium for marketing in 1997, and the drug is successfully marketed there under the trade name Pariet®. Pariet® was approved in the United Kingdom in May 1998, and for marketing in all 14 other European Union countries beginning in September 1998. References 1. NIH, Gastroesophageal Reflux Disease (Hiatal Hernia and Heartburn). NIH Publication No. 94-882, September 1994